Liu Dinghong, Rong Li, Gao Yanlin, Cheng Wei, Zhao Sheng
Department of Clinical Medicine, Bengbu Medical University Hospital, Bengbu, China.
Department of Cardiovascular Medicine, Second People's Hospital of Anhui Province, Hefei, China.
J Coll Physicians Surg Pak. 2025 Jan;35(1):25-29. doi: 10.29271/jcpsp.2025.01.25.
To explore the prognostic significance of Sestrin-2 and Galectin-3 levels in atrial fibrillation complicated by left atrial remodelling, aiming to offer novel insights for prevention, treatment, and follow-up strategies.
Analytical study. Place and Duration of the Study: Department of Cardiology, Second People's Hospital of Anhui Province, Hefei, China, from January 2021 to December 2023.
A total of 188 patients with atrial fibrillation were enrolled and divided into two groups based on the presence or absence of atrial remodelling. Serum levels of Sestrin-2 and Galectin-3, along with baseline clinical data, laboratory examinations, and Doppler echocardiography results, were compared between the groups.
The atrial remodelling group showed significantly higher levels of age, AST, Sestrin-2, Galectin-3, and left atrial diameter compared to the non-atrial remodelling group (p <0.05). Multivariate logistic regression analysis indicated that both Sestrin-2 and Galectin-3 were independent risk factors associated with atrial remodelling in patients with atrial fibrillation (p <0.05). The combined assessment of Sestrin-2 and Galectin-3 yielded an area under the receiver operating characteristic (ROC) curve of 0.854, facilitating precise identification of the incidence of atrial fibrillation.
The study found that serum levels of Sestrin-2 and Galectin-3 were significantly elevated in the atrial remodelling group compared to the non-atrial remodelling group, suggesting their potential clinical utility in predicting atrial remodelling in patients with atrial fibrillation. These findings are significant for the prevention and treatment of this condition.
Atrial fibrillation, Sestrin-2, Galectin-3, Atrial remodelling.
探讨Sestrin-2和半乳糖凝集素-3水平在合并左心房重构的心房颤动中的预后意义，旨在为预防、治疗及随访策略提供新的见解。
分析性研究。研究地点和时间：中国合肥安徽省第二人民医院心内科，2021年1月至2023年12月。
共纳入188例心房颤动患者，根据是否存在心房重构分为两组。比较两组患者的Sestrin-2和半乳糖凝集素-3血清水平，以及基线临床资料、实验室检查和多普勒超声心动图结果。
与非心房重构组相比，心房重构组患者的年龄、谷草转氨酶、Sestrin-2、半乳糖凝集素-3水平及左心房直径显著更高（p<0.05）。多因素logistic回归分析表明，Sestrin-2和半乳糖凝集素-3均为心房颤动患者心房重构的独立危险因素（p<0.05）。Sestrin-2和半乳糖凝集素-3的联合评估得出受试者工作特征（ROC）曲线下面积为0.854，有助于准确识别心房颤动的发生率。
研究发现，与非心房重构组相比，心房重构组患者的Sestrin-2和半乳糖凝集素-3血清水平显著升高，提示它们在预测心房颤动患者心房重构方面具有潜在的临床应用价值。这些发现对该病的预防和治疗具有重要意义。
心房颤动；Sestrin-2；半乳糖凝集素-3；心房重构
